Suwannutsiri Thitaree, Arreenich Peerada, Sombuntham Premsuda
Taksin Hospital, Medical Service Department, Bangkok Metropolitan Administration, Bangkok 10600, Thailand.
Department of Otolaryngology-Head and Neck Surgery, King Chulalongkorn Memorial Hospital, Bangkok 10330 Thailand.
Asian Biomed (Res Rev News). 2024 Dec 16;18(6):297-302. doi: 10.2478/abm-2024-0037. eCollection 2024 Dec.
The COVID-19 pandemic first emerged in December 2019 and rapidly spread globally, including Thailand. While respiratory symptoms remain the primary manifestation of the disease, upper respiratory tract symptoms, including dysphonia, have been reported in various studies.
To determine the prevalence of dysphonia in non-hospitalized Thai COVID-19 patients and identify associated factors using the Thai-Voice Handicap Index-10.
This study investigates the prevalence of dysphonia and associated factors in non-hospitalized Thai COVID-19 patients. Conducted from September 2022 to February 2023, it enrolled healthcare workers who tested positive for COVID-19 but were not hospitalized.
Among 82 patients, 53 (64.6%) reported dysphonia, which was significantly associated with cough ( = 0.013) and nasal discharge ( = 0.047). Substantial improvement was observed at the 3-month follow-up (73.6%). Vaccination may serve as a protective factor (crude odds ratio < 1).
The prevalence of dysphonia among non-hospitalized COVID-19 patients in Thailand is 63.6%, linked to cough and nasal congestion, with symptoms likely to subside within 3 months.
2019年12月首次出现的新冠疫情迅速在全球传播，包括泰国。虽然呼吸道症状仍是该疾病的主要表现，但多项研究报告了包括发声困难在内的上呼吸道症状。
使用泰语嗓音障碍指数-10确定泰国非住院新冠患者发声困难的患病率，并确定相关因素。
本研究调查泰国非住院新冠患者发声困难的患病率及相关因素。研究于2022年9月至2023年2月进行，纳入新冠病毒检测呈阳性但未住院的医护人员。
82例患者中，53例（64.6%）报告有发声困难，这与咳嗽（P = 0.013）和流鼻涕（P = 0.047）显著相关。在3个月的随访中观察到症状有显著改善（73.6%）。接种疫苗可能是一个保护因素（粗比值比<1）。
泰国非住院新冠患者发声困难的患病率为63.6%，与咳嗽和鼻塞有关，症状可能在3个月内缓解。
